The China Myasthenia Gravis Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 8.2% during the forecast period.
Myasthenia gravis (MG) is an organ-specific autoimmune disorder of the neuromuscular junction, characterized by specific autoantibodies against skeletal muscular antigens in the postsynaptic membrane. And 85% of all patients experience generalized myasthenia gravis affecting proximal muscles of the extremities and the trunk. The annual incidence of myasthenia gravis in China is 29400 and the prevalence is 165600 in 2019. China has a large number of patients (650,000) who are suffering from MG disease. The admission mortality rate was 14.69%. Most cases of new onset MG occurred in the seventh decade of life. In China, the incidence rate of myasthenic crisis (4.81%) and mortality rate (6.4%) are less as compared to the USA.
The market is majorly driven by the rising geriatric population (12.57% by end of 2019). The mean age of disease diagnosis was 52.2 years, with adults 55.9 years and children 8.9 years. Key factors that are driving the market growth include rising adoption of immunotherapies, approval of promising drugs, emergence of biologics, increase in incidence (annually in China 29400) and increasing awareness of rare diseases.
However, the side effects caused by several therapeutics are restraining market growth. Some of the products are withdrawn from the market due to serious side effects. In April 2019, high dose combination of Cholinesterase Inhibitors (ChEIs) and Calcineurine Inhibitors (CNIs) such as Mestinon and Prograf are responsible for severe muscle cramps in myasthenia gravis patients. High cost of treatment also impacts the growth of the market.